UCB raises 2026 revenue growth outlook to low twenties at constant exchange rates

• UCB raised its 2026 revenue growth forecast to the low-20% range at constant exchange rates, from the low-to-mid-teens.
• Adjusted EBITDA growth is now expected in the low-to-mid-40% range at constant exchange rates, versus the mid-teens to low-20% range previously.
• Stronger U.S. Bimzelx performance reflects robust patient demand and favorable net pricing; Cimzia also benefited from volume growth and better pricing.
• Higher revenue growth is expected to drive greater operating leverage and significant margin expansion.
• Guidance excludes Priority Review Voucher sale proceeds, offering additional low- to mid-single-digit percentage-point uplifts to revenue and adjusted EBITDA, respectively.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. UCB SA published the original content used to generate this news brief on October 22, 2026, and is solely responsible for the information contained therein.